Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00621842 · ClinicalTrials.gov registry record · Phase 3

Lamotrigine for Symptoms of Geriatric Bipolar Depression

A Phase 3 study, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
Phase 3
Development phase
57
Enrollment target

NCT00621842 is a Phase 3 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 57 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00621842, a Phase 3 study, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
Phase 3
Development phase
57 participants
Enrollment target

Study Summary

This is a 12-week, open label trial of lamotrigine for older adults (age 60 and older) with type I or type II Bipolar depression. Non-demented older adults with Bipolar I or II depression, confirmed via the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (DSM) - Patient edition (SCID-I/P) and meeting inclusion criteria for depressive symptom severity (score of 18 or greater on the Hamilton Depression Rating Scale/HAM-D-24) will receive add-on lamotrigine dosed to a target of 200 mg/day.

Interventions

  • DRUG Lamotrigine regular tablet formulation
  • DRUG Lamotrigine novel formulation

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2008-01
Est. Completion 2010-03
Phase Phase 3

What the Registry Record Tells You About NCT00621842

The ClinicalTrials.gov registry entry for NCT00621842 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Lamotrigine regular tablet formulation is the first listed.

NCT00621842 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00621842 about?

NCT00621842 is a clinical study titled "Lamotrigine for Symptoms of Geriatric Bipolar Depression". This is a 12-week, open label trial of lamotrigine for older adults (age 60 and older) with type I or type II Bipolar depression. Non-demented older adults with Bipolar I or II depression, confirmed via the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders ...

What is the current status of trial NCT00621842?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2008-01. Estimated completion is 2010-03.

What interventions are being tested in trial NCT00621842?

The interventions under investigation include: Lamotrigine regular tablet formulation (DRUG), Lamotrigine novel formulation (DRUG).

Who is sponsoring clinical trial NCT00621842?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.